# The Mechanism and Current State of Non-Alcoholic Fatty Liver Disease Pharmacological Therapy: A Review

**[1]Nithyasree S, [2]Abarnadevika A, [3]Ariharasivakumar G, [4]Malathi S, [5]Vignesh M**

Department of pharmacology
KMCH College of pharmacy
Coimbatore.

*Abstract-* **This review comprehensively explores the factors influencing the development, progression, and complications of liver steatosis and nonalcoholic fatty liver disease (NAFLD). This condition is characterized by hepatic fat accumulation, encompasses nonalcoholic fatty liver (NAFL) and nonalcoholic steatohepatitis (NASH). The rising global prevalence of obesity and insulin resistance has made these conditions leading causes of chronic liver disease. NASH can evolve into fibrosis, cirrhosis, and hepatocellular carcinoma, posing significant health risks. The pathophysiology of NAFLD is complex, involving a combination of genetic and environmental factors. The traditional "two hits" model has been replaced by "multiple-parallel hits" model, emphasizing the interplay of genetic predisposition, obesity, insulin resistance, and gut microbiota changes. The role of immune cells, particularly macrophages, NASH development is discussed, highlighting potential therapeutic targets. Drug-induced NAFLD is examined, focusing on mechanisms leading to steatosis and liver damage. Several drugs, including amiodarone, tamoxifen, and valproate, disrupt mitochondrial function and induce lipogenesis, contributing to drug-induced fatty liver. Pharmacological therapies for NAFLD, targeting insulin resistance, oxidative stress, and lipotoxicity, are reviewed. Insulin sensitizers such as thiazolidinediones and metformin, antioxidants like vitamin E and pentoxifylline, and drugs that decrease cholesterol are discussed. Additionally, agents activating nuclear transcription factors (e.g.FXR agonists and PPAR agonists) and cytokine modulation are explored as potential treatments. In conclusion, the review underscores the multifaceted nature of NAFLD and provides insights into current and emerging pharmacological therapies. Despite the challenges, ongoing research offers hope for effective treatments in the future, emphasizing need for a comprehensive approach considering individual patient profiles and disease stages.**

*Keywords:* **Non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), insulin resistance, obesity, hepatocellular carcinoma (HCC), antioxidant.**

## 1. INTRODUCTION

This review aims to provide information for a complete understanding of the factors that impact the development, progression, and complications of liver steatosis and nonalcoholic fatty liver disease (NAFLD), as well as the treatments that have been undergone for this disease. When there are no other factors that lead to secondary liver fat accumulation, hepatic steatosis—the ectopic buildup of fat in hepatitis defines nonalcoholic fatty liver disease (NAFLD). While a small accumulation of fat in the liver is normal for healthy adults, when fat deposits in at least 5% of liver cells, it's considered abnormal. This condition encompasses both nonalcoholic fatty liver (NAFL) and nonalcoholic steatohepatitis (NASH), the latter diagnosed when there's evidence of inflammation and liver cell damage alongside fat buildup. With the increasing global prevalence of obesity and insulin resistance, these conditions have become the primary causes of long-term liver issues. NASH can progress to liver scarring, cirrhosis, and even liver cancer, affecting around 30% to 40% of patients with fibrosis development.[1] Acute liver steatosis gives way to non-alcoholic steatohepatitis (NASH) and, in more advanced situations, liver cirrhosis and fibrosis. HCC is more likely to occur in NASH patients who already have fibrosis or cirrhosis. The histological features of the illness spectrum are unique to each stage. Fat droplet formation in hepatocytes is referred to as simple hepatic steatosis. Hepatocellular damage, ballooning, and inflammation appear when the condition advances to NASH. Cirrhosis eventually results from liver fibrosis brought on by the further deterioration of NASH [2]. NAFLD is typically associated with a variety of metabolic problems, particularly insulin resistance (IR), type 2 diabetes (T2DM), hyperlipidemia, and obesity, all of which are characteristics of the metabolic syndrome.

## 2. PATHOPHYSIOLOGY

The etiology of non-alcoholic fatty liver disease (NAFLD) is intricate and multifaceted, including several systemic abnormalities. According to the classic "two hits" idea, there is an intrahepatic buildup of fatty acids as the first "hit," and other elements like oxidative stress or mitochondrial dysfunction are added in the second "hit. This idea has been deemed insufficiently complex to explain the pathophysiology of nonalcoholic fatty liver disease. Hence, it has been superseded by the "multiple-parallel hits" model, which appears to better accurately depict the course of NAFLD formation and progression. In this model, individuals with a genetic predisposition operate in concert with one another and in parallel.[3] The multiplehits theory postulates that obesity, the development of insulin resistance, and changes to the gut microbiota are caused by a combination of hereditary and environmental variables related to food patterns. Adipose tissue lipolysis and hepatic de novo lipogenesis is encouraged by insulin resistance, which increases the flow of fatty acids into the liver. Insulin resistance can also result in dysfunctional adipose tissue, which triggers the release of inflammatory cytokines.[4]




**Fig. 1: Progression of fatty liver disease**

## 3.MECHANISM INVOLVED IN NAFLD

### 3.1 OBESITY

The excess fatty acids (TGs) in tissues are gathered by adipocytes, which play a crucialrole in mediating systemic lipid storage and adipokine release. These TGs subsequently have an impact on several processes, such as lipid metabolism, glucose control, and inflammation.[5] The main source of fat in individuals with non-alcoholic fatty liver disease (NAFLD) is the free fatty acids (FFAs) produced by TG lipolysis. One typical consequence of NAFLD is the development of insulin resistance, which is facilitated by these FFAs.[6] The activity of lipolysisin visceral adipose tissue is higher than that in subcutaneous adipose tissue, which reasons sufferers with visceral fats accumulation-precipitated vital weight problems to be universally insulin resistant and much more likely to broaden NAFLD secondary to their growing FFA content. Adiponectin is a secretory adipokine that is unique to adipose tissue. It can limit fat-free buildup by inducing lipid transfer and FFA oxidation, both of which have a matching receptor in the liver.[7] The distinctive characteristic of non-alcoholic fatty liver disease (NAFLD), hypoadiponectinemia, implies that adiponectin, acting as a competitor of tumor necrosis factor α (TNF-α), has anti-lipogenic as well as anti-inflammatory activities that may protect the liver from damage by maintaining the proper balance between both pro- and anti- inflammatory cytokines in hepatocytes. [8]

### 3.2 DIABETES

Generally, type 2 diabetes mellitus (T2DM), diabetes, and complications associated with obesity and diabetes share similarities with nonalcoholic fatty liver disease (NAFLD) concerning clinical presentation, underlying mechanisms, and treatment options. Hyperlipidemia and insulin resistance are outcomes of obesity and reduced production of adiponectin due to prolonged calorie excess.[9] A considerable proportion of middle-aged Japanese individuals, approximately 29%, have NAFLD, often coexisting with metabolic syndrome, as evidenced by research on health examinations in Japan.[10] Moreover, hepatic steatosis not only contributes to peripheral insulin resistance and

excessive endocrine responses, key features of type 2 diabetes, but also leads to an inherent defect causing an excessof nonesterified fatty acids.[11]

**3.3 T-cells in the development of NASH/ NAFLD**

Immune cells, including macrophages, Th1/Th2 cells, natural killer cells, and T regulatory cells (T regs), have been studied for their possible therapeutic value as well as theirroles in the pathophysiology of non-alcoholic steatohepatitis (NASH). In particular, systemic insulin resistance and, eventually, the condition is triggered by inflammation-related substances produced primarily by hepatic macrophages, which can be made up of brought-in bone marrow-derived macrophages and resident Kupffer cells.[12] When provoked by different factors, macrophages in tissues develop and take on specific functional phenotypes. In general, ligands that bind to toll-like receptors (TLRs), such as LPS (lipopolysaccharide) and interferon beta (IFN-γ), cause classical M1 activation, while IL-4 and IL-13 generate alternative M2 activation.[13] The many forms of activation of macrophages are controlled through a network of molecules that signal transcription factors, epigenetic processes, and posttranscriptional regulators. NAFLD, obesity, as well as associated illnesses, cancer, infections, or persistent inflammation, may be caused by the deregulation and polarization of M1/M2 macrophages.M2macrophages/Kupffer cells have been shown to protect against NAFLD and alcoholic fatty liver disease by inducing M1 macrophage/Kupffer cell death. As a result, specific medicines

**3.4 DRUGS INDUCED NAFLD**

It has been proposed that the primary processes in DIFLD development are lipogenesis and the production of free radicals, which induce oxidative stress in hepatocytes. [16,17] In the rat livers, amiodarone improved the levels of short, medium, and long-chain acylcarnitine's; acetylcarnitine levels improved most significantly. The interruptions observed in healthy tissuedue to amiodarone's effects on mitochondrial fatty acid oxidation (mtFAO) likely stem from its ability to block complexes I and II of the mitochondrial respiratory chain (MRC), consequently preventing the direct conversion of acyl-CoA to acetyl-CoA during mitochondrial β-oxidation.[18,19] Triggering de novo lipogenesis by upregulating the expression of genes associated with lipogenesis, including acyl-CoA desaturase, ATP-citrate synthesis, lipid synthase, thyroid hormone-inducible liver protein, and cholesterol regulatory element- binding protein 1, is another established mechanism of amiodarone-induced DIFLD. Additionally, it was found that amiodarone treatment caused the genes perilipin-4 as well as adipose differentiation-related proteins, which are involved with the formation of lipid droplets, to become overexpressed in vitro.[20] Tamoxifen is a cationic amphiphilic chemical that accumulates in liver tissue and causes liver harm, just like amiodarone.[21] It also works by inhibiting mtFAO and inducing de novo lipogenesis to produce its toxic impact.[22] The elevation of SREBP-1c and its associated downstream lipid production gene targets is a possibility for the formation of steatosis in the liver.[23] Some of the drugs induced nafld and their mechanism are listed below in Table.1

**TABLE 1 - DRUG INDUCED NAFLD/NASH AND THEIR MECHANISM**

| | |
|---|---|
| Amiodarone | A lower level in mtFAO, suppression of MRC I and II complexes, an increase in acetylcarnitine levels, and inhibition of CPT1 enzyme activity. A higher level of expression of the genes SREBP1, THRSP,ACLY, FASN, SCD1, PLIN4, and ADFP initiates de novo lipogenesis. This decrease in GSH concentrations. |
| Tamoxifen | De novo lipogenesis is induced by upregulating SREBP1c and its downstream genes, resulting in impairment of the mtFAO. MTP expression, as well as VLDL production and assembly, are stimulated. decrease in GSH concentration. |
| Methotrexate | Impact on mitochondrial function via impeding the entry of folate tomitochondria, producing reactive oxygen species, and damaging theintestinal epithelial barrier. |
| 5-Fluorouracil, irinotecan,asparaginase | Hepatocytes with impaired mtFAO and increased ROS accumulation |
| Valproate | Reduced CoA levels and competition for mtFAO with other FFAs. Weight gain and the development of systemic insulin resistance. |
| Tetracycline | Reduction in the expression of the PAARα, CPTI, FABP1, and MTP enzymes—all of which are implicated in mtFAO. ROS production is increased when ATF4 is activated. |
| NRTIs | Inhibition of human DNA polymerase γ, reduction in mitochondrial DNA replication, and oxidative stress induction. |

Lipid accretion enhances the synthesisof the microsomal lipid transfer protein, which is linked to VLDL assembly and secretion.[24] Hepatocytes store methotrexate, a substance with toxic effects on the liver. It is especially true of its

polyglutamated derivative.[25] There are several theories regarding how methotrexate causes excessive liver damage. These include blocking folate's ability to enter mitochondria, creating a problem within the mitochondria and releasing reactive oxygen species (ROS), andfinally inducing caspase-dependent death. [26,27] Fluorouracil, irinotecan, and L-asparaginase are examples of hepatosteatotic drugs that reduce mtFAO while increasing hepatocyte ROS production. [28,29] Triglycerides build up, and steatosis occurs when valproate, a branched-chainfatty acid, interferes with the mtFAO. As a substrate for mtFAO pathways, valproate in its free acid form might compete with other free fatty acids for binding sites. It binds with coenzyme A upon entry into the hepatic mitochondria, resulting in an enzyme deficit. [30] The well-known cause of DIFLD is tetracycline. Several factors contribute to the toxic effect of drug-induced fatty liver disease (DIFLD), including inhibition of mitochondrial fatty acid oxidation (mtFAO), suppression of microsomal triglyceride transfer protein (MTP) enzyme leading to very low-density lipoprotein (VLDL) accumulation, downregulation of mtFAO-related genes such as carnitine palmitoyltransferase I and fatty acid-binding protein 1, and increased reactive oxygen species (ROS) production mediated by the transcription factor ATF4, which upregulates CYP2E1.[31-34] Additionally, drugs like doxycycline and minocycline exacerbate ROS generation through ATF4. Examples of nucleoside reverse transcriptase inhibitors like reversanosine, stavudine, tenofovir, zidovudine, and abacavir inhibit human DNA polymerasegamma, thereby reducing mitochondrial DNA replication. [35,36]

## 4.PHARMACOLOGICAL THERAPY

Most patients cannot be successfully or sustainably treated with diet and lifestyle modifications. Patients requiring pharmaceutical therapy primarily targeted at reducing hepaticinflammation, fibrosis, and steatohepatitis include those who do not respond well to lifestyle interventions or who have a very advanced illness (significant fibrosis).

### 4.1 INSULIN SENSITIZERS

Insulin resistance is a primary cause of an abnormal accumulation of fats in the liver and is essential for the development and progression of fibrosis and steatohepatitis. The following list of pharmaceuticals focuses on improving insulin resistance.

**Thiazolidinediones**

Glitazones, or thiazolidinediones (TZD), are the most strongly supported evidence- based medications studied for the treatment of nonalcoholic steatohepatitis (NASH).[37] Glitazone usage in NASH is advised by current recommendations. Insulin-resistant, large pre- adipocytes are encouraged to differentiate into tiny, proliferating, insulin-sensitive adipocytes by glitazones.[38] When lipogenic genes and lipoprotein lipase (LPL) are induced, fatty acid production and absorption in adipose tissue are increased. This causes the load of free fatty acids (FFA) to be directed towards adipocytes rather than the liver.[39] Insulin sensitivity improves as a result, even with a rise in fatty tissue. Glitazones enhance the production of adiponectin in the liver and muscles, which is an insulin-sensitizing and anti-steatogenic hormone promoting fatty acid beta-oxidation. [40,41] This action facilitates the transfer of fat fromectopic tissues to adipose tissue while increasing adiponectin levels. Additionally, glitazones upregulate glucose transporter type-4 (GLUT-4) and AMP-activated protein kinase expressionin muscle and adipose tissue, leading to reduced insulin resistance. [42, 43]

**Metformin:**

Metformin is an oral biguanide that decreases hepatic glucose synthesis and raises peripheral glucose consumption.[44] It is another insulin-sensitizing drug. It is approved for people with type 2 T2D to use metformin. [45[ With a shift in redox state, it reduces the amount of glucose produced endogenously, activates AMP-activated protein kinase, and inhibits the mitochondrial glycerophosphate dehydrogenase shuttle.[46] Although metformin is regarded as a safe medication, its effectiveness in treating non-alcoholic steatohepatitis (NASH) is not established.[47]

### 4.2 ANTIOXIDANTS

The development of NASH and liver damage are thought to be facilitated by increasedoxidative stress and impaired antioxidant defense systems, which have been thoroughly investigated throughout the various phases of non-alcoholic fatty liver disease (NAFLD). The following is a list of some of the antioxidant-active medications being utilized to treat NASH.

**Vitamin E**

Vitamin E is a fat-soluble substance that may be found in many different substances that are members of the tocopherol and tocotrienol families. The phospholipid bilayer of cell membranes contains vitamin E, a substance that helps prevent oxidative damage brought on byfree radicals.[41] It guards against inflammation of the liver by preventing intrinsic pathways ofapoptosis and mitigating mitochondrial toxicity. [47,48] Furthermore, it has been shown to possess non-antioxidant characteristics and can modify gene expression, cell-to-cell communication, and nuclear factor kappa B (NF-kB)-dependent inflammatory pathways. [49,50]

**Pentoxifylline**

Pentoxifylline, a non-selective phosphodiesterase inhibitor, is employed in the treatment of peripheral vascular disease.[51] According to research on animals, pentoxifylline has an antioxidant effect and prevents the release of

cytokines that promote inflammation.[52] These outcomes were validated in vivo, as pentoxifylline markedly reduced steatohepatitis in a dietary NASH model lacking in methionine and choline.[53]

**4.3 LIPOTOXICITY BASED TARGETS**

The progression from steatosis to nonalcoholic steatohepatitis (NASH) may be signaledby an accumulation of lipotoxic intermediates from triglyceride production or breakdown.[54]

De novo lipogenesis (DNL), the biological process of synthesizing fatty acids from acetyl-CoA subunits, primarily occurring in the liver and often fueled by carbohydrate catabolism, plays a significant role in NASH. The rate-limiting step in DNL is catalyzed by acetyl-CoA carboxylase (ACC), which has two main isoforms in mammals: ACC1 and ACC2. Another appealing strategy to regulate fatty acid production in lipogenic tissues is the pharmacological suppression of ACC. GS-0976 inhibits the carboxylase acetyl-CoA. [55,56]

**4.4 DRUGS THAT DECREASE CHOLESTEROL:**

Certain pharmaceutical therapies may target cholesterol, a major toxic lipid mediator of liver disease. Stearoyl-CoA desaturase 1 (SCD-1) is an enzyme that catalyzes the formation of mono-unsaturated fatty acids, especially oleic acid.[57] Insulin sensitivity increases when SCD-1 is inhibited or deficient, which decreases hepatic steatosis. It has been noted that obese NASH patients exhibit increased SCD-1 activity. The SCD-1 inhibitor Aramchol was found to lower the amount of fat in the liver in 60 NAFLD patients in a double-blind, placebo-controlledclinical study.[58] Statins are a family of medications that decrease cholesterol; they are often referred to as HMG-CoA reductase inhibitors. It has been found that statins only slightly ameliorate steatosis.[59] To lower plasma cholesterol and lower the risk of cardiovascular disease (CVD), these are the first-choice medications.[60] When it comes to people with NAFLD and NASH, CVD is one of the main causes of mortality.[61] Statins have no positive effects on the histology of the liver in NASH patients.[62] As a result, statin therapy for NASH is not currently advised.[59] Statins are advised for cardiovascular endpoints in NAFLD patientsdue to concurrent metabolic comorbidities. Because statins are known to reduce aminotransferase levels in people with metabolic syndrome, several studies have examined their safety in cases of hepatotoxicity. [63,64]

**4.5 NUCLEAR TRANSCRIPTION FACTOR ACTIVATION**

Nuclear transcription factors are molecules that regulate the transcription of specific genes upon binding to their ligands. They hold promise as therapeutic targets for treating non- alcoholic steatohepatitis (NASH).

**Agonists for the farnesoid X receptor (FXR)**

FXR agonists, part of the nuclear receptor superfamily, play a crucial role in modulating metabolic pathways such as glucose homeostasis, inflammation, and fibrogenesis. In individuals with NASH, there's a correlation between disease severity and hepatic FXR expression levels.[65] FXR is expressed in various organs including the adrenal glands, liver, kidneys, and intestines, regulating liposomal metabolism and bile acid production and circulation.[66] Activation of FXR protects hepatocytes from bile acid-induced toxicity and influences hepatic lipogenesis, cholesterol synthesis, glucose homeostasis, and bile acid production.[67,68] Animal studies suggest that FXR deficiency coupled with a high-fat diet leads to liver steatosis, inflammation, and fibrosis.[69] FXR agonists have shown promise in promoting the resolution of steatohepatitis and fibrosis in rodent models of diet-induced NASH, potentially preventing its development.[70] Synthetic FXR agonists are under investigation for treating NASH and other liver diseases.[71]

**Agonists for the farnesoid X receptor (FXR)**

FXR agonists, part of the nuclear receptor superfamily, play a crucial role in modulating metabolic pathways such as glucose homeostasis, inflammation, and fibrogenesis. In individuals with NASH, there's a correlation between disease severity and hepatic FXR expression levels.[65] FXR is expressed in various organs including the adrenal glands, liver, kidneys, and intestines, regulating liposomal metabolism and bile acid production and circulation.[66] Activation of FXR protects hepatocytes from bile acid-induced toxicity and influences hepatic lipogenesis, cholesterol synthesis, glucose homeostasis, and bile acid production.[67,68] Animal studies suggest that FXR deficiency coupled with a high-fat diet leads to liver steatosis, inflammation, and fibrosis.[69] FXR agonists have shown promise in promoting the resolution of steatohepatitis and fibrosis in rodent models of diet-induced NASH, potentially preventing its development.[70] Synthetic FXR agonists are under investigation for treating NASH and other liver diseases.[71]

**Tropifexor (LJN-452):**

Tropifexor (LJN-452) is a highly strong non-bile acid FXR agonist that can activate target genes at extremely low doses. Preclinical NASH models have demonstrated the high efficacy of tropifexor.[72] Tropifexor and cenicriviroc's safety and effectiveness in treating individuals with fibrosis and biopsy-proven NASH are being assessed in the current phase 2 RCT FLIGHTFXR.[73]

**4.6PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPARS)**

Peroxisome proliferator-activated receptors (PPARs) belong to a class of nuclear receptors found in various tissues including the kidney, liver, adipose tissue, heart, and skeletal muscle. They regulate the transcription of metabolic processes such as gluconeogenesis, lipid transport,and β oxidation.[74] PPARs are divided into three isotypes: PPARα, PPARβ (also known as PPARδ), and PPARγ, with differing tissue distributions despite targeting the same DNA

region. PPARs form heterodimers with the retinoid X receptor (RXR) to control gene transcription. PPARα upregulates enzymes involved in fatty acid oxidation, microsomal ω- oxidation, and ketogenesis, shifting hepatic metabolism towards lipid oxidation.[75,76] Activation of PPARα increases triglyceride clearance by upregulating lipoprotein lipase (LPL) production and downregulating hepatic secretion of APOCIII, an LPL inhibitor.[77] Additionally, PPARα decreases the production of pro-inflammatory cytokines such as interleukin 1 (IL-1), IL-6, and tumor necrosis factor (TNF), as well as adhesion molecules like intercellular adhesion molecule 1 (ICAM1) and vascular cell adhesion molecule 1 (VCAM1).[78,79] These anti-inflammatory effects are hepatoprotective against inflammation and fibrosis induced by a methionine-choline-deficient diet and are independent of peroxisome proliferator response elements (PPRE).[80]

**Elafibranor:**

Elafibranor is an agonist of PPAR-alpha/delta (α/δ) that regulates insulin and lipidmetabolism in NAFLD and NASH.[81]

**4.7 CYTOKINES**

Liver cells produce cytokines, essential signaling molecules involved in cellular communication and inflammation-related diseases.[82] Subclasses of cytokines include transforming growth factors (TGF), interleukins (IL), tumor necrosis factor (TNF), colony- stimulating factors, and chemokines. In non-alcoholic fatty liver disease (NAFLD), characterized by lipid accumulation and inflammation, cytokines likely play a pivotal role, promoting hepatic inflammation, steatosis, cell apoptosis and necrosis, and fibrosis. Pro- inflammatory cytokines like TNFα and the IL family are thought to regulate key aspects of liver disease.

**Tumor necrosis factor-alpha (TNF-α)** is a pro-inflammatory cytokine that is released by several tissues, including endothelium, adipose tissue, and neurons, as well as monocytes/macrophages, neutrophils, and T-cells. It is linked to insulin resistance, which is connected to obesity.[83] Insulin sensitivity was enhanced in genetic and dietary models of obesity in mice devoid of TNFα. [84] TNFα expression is shown to be elevated in obesity andto decrease with weight reduction, according to clinical trials [85,86] suggesting a role for TNFαin both metabolic dysregulation and obesity.[87]

**Transforming growth factor-beta (TGF-β):**

TGF-β is a cytokine known for its immunosuppressive effects and promotion of fibrosis.[88] TGF-β1, a major isoform, plays a significant role in hepatic fibrosis by inducing stellate cell activation.[89,90] Its expression is elevated in hepatic fibrosis models and in patients with liver fibrosis.[91] Given that liver fibrosis is a significant predictor of mortality in NAFLD patients, researchers are increasingly focusing on developing therapies targeting fibrogenesis-related components.[92] TGF-β, a crucial pro-fibrogenic cytokine, is implicated in liver fibrosis progression. Persistent liver injury leads to elevated TGF-β levels, which activate stellate cellsinto myofibroblasts and contribute to hepatocyte cell death, both promoting liver fibrosis. TGF- β signaling pathways, including TAK1- and Smad-dependent signaling, regulate processes such as carcinogenesis, fibrosis, cell survival, and proliferation.[93]

## CONCLUSION

Obesity and insulin resistance are major contributors to the accumulation of triglycerides and free fatty acids in the liver, driving the increasing prevalence of non-alcoholicfatty liver disease (NAFLD) both in India and globally. While liver steatosis is often benign, the progression of fibrosis indicates a poor prognosis. Numerous risk factors for NAFLD development are linked to metabolic disturbances and insulin resistance. The expanding rangeof medications in development offers promising prospects for treating non-alcoholic steatohepatitis (NASH) in the future. In the meantime, first-line treatments such as vitamin E and pioglitazone remain effective for carefully selected individuals, regardless of diabetes status.

## FUTURE PROSPECTS:

**Precision Medicine:**

With advancements in genetic testing and understanding individual variations indisease susceptibility and response to treatment, personalized or precision medicine approaches for NAFLD/NASH are likely to become more prevalent. Tailoring treatments based on genetic makeup and other individual factors could improve efficacy and reduce side effects.

**Novel Therapeutics:**

Ongoing research is focused on developing new drugs targeting specific pathways involved in NAFLD/NASH pathogenesis, such as inhibitors of lipogenesis, antioxidants, and agents modulating nuclear transcription factors like FXR and PPARs. These novel therapeuticsaim to provide more effective and targeted treatments with fewer adverse effects.

**Combination Therapy:**

Given the complex nature of NAFLD/NASH, combination therapies involving drugs targeting different aspects of the disease process are being explored. Combining insulin sensitizers, antioxidants, and agents affecting lipid metabolism or inflammation may offer synergistic effects and better outcomes for patients.

**Non-Pharmacological Interventions:**
In addition to drug therapy, non-pharmacological interventions such as lifestyle modifications, dietary changes, and exercise regimens will continue to play a crucial role in managing NAFLD/NASH. Integrated approaches combining pharmacotherapy with lifestyle interventions may yield the best results.

**Biomarker Development:**
Identifying reliable biomarkers for diagnosing and monitoring NAFLD/NASH progression is an area of active research. Biomarkers reflecting disease activity, severity, and response to treatment could facilitate early detection, risk stratification, and treatment monitoring.

**Regenerative Medicine:**
Advancements in regenerative medicine, including stem cell therapy and tissue engineering, hold promise for repairing liver damage caused by NAFLD/NASH. Regenerative approaches aim to restore liver function and reverse fibrosis, offering potential long-term solutions for patients with advanced disease.

Overall, the future of NAFLD/NASH management looks promising, with ongoing research efforts focused on developing more effective, personalized, and holistic treatment strategies to address this growing global health concern.

**REFERENCES:**


1. Pang Y, Kartsonaki C, Turnbull I, Guo Y, Chen Y, Clarke R, et al. Adiposity in relation to risks of fatty liver, cirrhosis and liver cancer: a prospective study of 0.5 million Chinese adults. Sci Rep. 2019; 9:785.
2. Lau JKC, Zhang X, Yu J. Animal models of non-alcoholic fatty liver disease: current perspectives and recent advances. J Pathol. 2017;241(1):36–44.
3. Başaranoglu M, Ormeci N. Nonalcoholic fatty liver disease: diagnosis, pathogenesis, and management. Turk J Gastroenterol. 2014;25(2):127–32.
4. Gariani K, Jornayvaz FR. Pathophysiology of NASH in endocrine diseases. Endocr Connect. 2021;10(2): R52–65.
5. Scherer PE. Adipose tissue: from lipid storage compartment to endocrine organ. Diabetes. 2006;55(6):1537–45.
6. Odegaard JI, Ricardo-Gonzalez RR, Red Eagle A, Vats D, Morel CR, Goforth MH, et al. Alternative M2 activation of Kupffer cells by PPARdelta ameliorates obesity-induced insulin resistance. Cell Metab. 2008;7(6):496–507.
7. Angulo P. GI epidemiology: nonalcoholic fatty liver disease. Aliment Pharmacol Ther. 2007;25(8):883–9.
8. Pagano C, Soardo G, Esposito W, Fallo F, Basan L, Donnini D, Federspil G, Sechi LA, Vettor R (2005) Plasma adiponectin is decreased in nonalcoholic fatty liver disease. Eur J Endocrinol 152:113–118
9. Rashid M, Roberts EA (2000) Nonalcoholic steatohepatitis in children. J Pediatr Gastroenterol Nutr 30:48–53
10. Jimba S, Nakagami T, Takahashi M, Wakamatsu T, Hirota Y, Iwamoto Y, Wasada T (2005) Prevalence of non-alcoholic fatty liver disease and its association with impaired glucose metabolism in Japanese adults. Diabet Med 22:1141–1145.
11. Bugianesi E, Gastaldelli A, Vanni E, Gambino R, Cassader M, Baldi S, Ponti V, Pagano G, Ferrannini E, Rizzetto M (2005) Insulin resistance in non-diabetic patients with non-alcoholic fatty liver dis ease: sites and mechanisms. Diabetologia 48:634–642
12. Odegaard JI, Ricardo-Gonzalez RR, Red Eagle A, Vats D, Morel CR, Goforth MH, Subramanian V, Mukundan L, Ferrante AW, Chawla A (2008) Alterna tive M2 activation of Kupffer cells by PPARdelta ameliorates obesity-induced insulin resistance. Cell Metab 7:496–507.
13. Sica A, Mantovani A (2012) Macrophage plasticity and polarization: in vivo veritas. J Clin Invest 122:787–795
14. Wan J, Benkdane M, Teixeira-Clerc F, Bonnafous S, Louvet A, Lafdil F, Pecker F, Tran A, Gual P, Mallat A et al (2014) M2 Kupffer cells promote M1 Kupffer cell apoptosis: a protective mechanism against alco holic and nonalcoholic fatty liver disease. Hepatology 59:130–142
15. Xue J, Sharma V, Hsieh MH, Chawla A, Murali R, Pandol SJ, Habtezion A (2015) Alternatively activated macrophages promote pancreatic fibrosis in chronic pancreatitis. Nat Commun 6:7158
16. Amacher DE, Chalasani N. Drug-induced hepatic steatosis. Semin Liver Dis 2014;34(2):205–214.
17. Miele L, Liguori A, Marrone G, Biolato M, Araneo C, Vaccaro FG, et al. Fatty liver and drugs: the two sides of the same coin. Eur Rev Med Pharmacol Sci 2017;21(1 Suppl):86–94.
18. Kim G, Choi HK, Lee H, Moon KS, Oh JH, Lee J, et al. Increased hepatic acylcarnitines after oral administration of amiodarone in rats. J Appl Toxicol 2020;40(7):1004–1013.

19. Fromenty B, Fisch C, Labbe G, Degott C, Deschamps D, Berson A, et al. Amiodarone inhibits the mitochondrial beta-oxidation of fatty acids and pro duces microvesicular steatosis of the liver in mice. J Pharmacol Exp Ther 1990;255(3):1371–1376.
20. Anthérieu S, Rogue A, Fromenty B, Guillouzo A, Robin MA. Induction of ve sicular steatosis by amiodarone and tetracycline is associated with up-reg ulation of lipogenic genes in HepaRG cells. Hepatology 2011;53(6):1895 1905.
21. Schumacher JD, Guo GL. Mechanistic review of drug-induced steatohepa titis. Toxicol Appl Pharmacol 2015;289(1):40–47.
22. Cole LK, Jacobs RL, Vance DE. Tamoxifen induces triacylglycerol accumula tion in the mouse liver by activation of fatty acid synthesis.Hepatology 2010;52(4):1258–1265.
23. Rabinowich L, Shibolet O. Drug induced steatohepatitis: An uncommon cul prit of a common disease. Biomed Res Int 2015; 2015:168905.
24. Zhao F, Xie P, Jiang J, Zhang L, A W, Zhan Y. The effect and mecha nism of tamoxifen-induced hepatocyte steatosis in vitro. Int J Mol Sci 2014;15(3):4019–4030.
25. Kremer JM, Galivan J, Streckfuss A, Kamen B. Methotrexate metabolism analysis in blood and liver of rheumatoid arthritis patients. Association with hepatic folate deficiency and formation of polyglutamates. Arthritis Rheum 1986;29(7):832–835.
26. Tabassum H, Parvez S, Pasha ST, Banerjee BD, Raisuddin S. Protective ef fect of lipoic acid against methotrexate-induced oxidative stress in liver mi tochondria. Food Chem Toxicol 2010;48(7):1973–1979.
27. Bath RK, Brar NK, Forouhar FA, Wu GY. A review of methotrexate-associated hepatotoxicity. J Dig Dis 2014;15(10):517–524.
28. Meunier L, Larrey D. Chemotherapy-associated steatohepatitis. Ann Hepa tol 2020;19(6):597–601.
29. Labbe G, Pessayre D, Fromenty B. Drug-induced liver injury through mito chondrial dysfunction: mechanisms and detection during preclinical safety studies. Fundam Clin Pharmacol 2008;22(4):335–353.
30. Miele L, Liguori A, Marrone G, Biolato M, Araneo C, Vaccaro FG, et al. Fatty liver and drugs: the two sides of the same coin. Eur Rev Med Pharmacol Sci 2017;21(1 Suppl):86–94.
31. Schumacher JD, Guo GL. Mechanistic review of drug-induced steatohepa titis. Toxicol Appl Pharmacol 2015;289(1):40–47.
32. Lettéron P, Sutton A, Mansouri A, Fromenty B, Pessayre D. Inhibition of microsomal triglyceride transfer protein: another mechanism for drug induced steatosis in mice. Hepatology 2003;38(1):133–140.
33. Szalowska E, van der Burg B, Man HY, Hendriksen PJ, Peijnenburg AA. Model steatogenic compounds (amiodarone, valproic acid, and tetracycline) alter lipid metabolism by different mechanisms in mouse liver slices. PLoS One 2014;9(1): e86795.
34. Brüning A, Brem GJ, Vogel M, Mylonas I. Tetracyclines cause cell stress-dependent ATF4 activation and mTOR inhibition. Exp Cell Res 2014;320(2):281–289.
35. Banerjee A, Abdelmegeed MA, Jang S, Song BJ. Zidovudine (AZT) and hepatic lipid accumulation: implication of inflammation, oxidative and endoplasmic reticulum stress mediators. PLoS One 2013;8(10): e76850.
36. Gardner K, Hall PA, Chinnery PF, Payne BA. HIV treatment and associated mi tochondrial pathology: review of 25 years of in vitro, animal, and human studies. Toxicol Pathol 2014;42(5):811–822.
37. Vuppalanchi R, Chalasani N. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management. Hepatology. 2009; 49(1):306–17.
38. Wu Z, Bucher NL, Farmer SR. Induction of peroxisome proliferator-activated receptor gamma during the conversion of 3T 3 fibroblasts into adipocytes is mediated by C/EBPbeta, C/EBPdelta, and glucocorticoids. Mol Cell Biol. 1996; 16(8):4128–36.
39. Kim JB, Spiegelman BM. ADD1/SREBP1 promotes adipocyte differentiation and gene expression linked to fatty acid metabolism. Genes Dev. 1996; 10(9):1096–107.
40. Yu JG, Javorschi S, Hevener AL, Kruszynska YT, Norman RA, Sinha M, Olefsky JM. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Diabetes. 2002; 51(10):2968–74.
41. Xu A, Wang Y, Keshaw H, Xu LY, Lam KS, Cooper GJ. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest. 2003; 112(1):91 100.
42. Saha AK, Avilucea PR, Ye JM, Assifi MM, Kraegen EW, Ruderman JB. Pioglitazone treatment activates AMP-activated protein kinase in rat liver and adipose tissue in vivo. Biochem Biophys Res Commun. 2004; 314(2):580–5.
43. Fryer LG, Parbu-Patel A, Carling D. The Anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways. J Biol Chem. 2002; 277(28):25226–32.
44. Kirpichnikov D, McFarlane SI, Sowers JR. Metformin: an update. Ann Intern Med. 2002; 137(1):25–33.

45. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, Musi N, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest. 2001; 108(8):1167–74.
46. Madiraju AK, Erion DM, Rahimi Y, Zhang XM, Braddock DT, Albright RA, Prigaro BJ, Wood JL, Bhanot S, MacDonald MJ, Jurczak MJ, et al. Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase. Nature. 2014; 510(7506):542–6.
47. Soden JS, Devereaux MW, Haas JE, Gumpricht E, Dahl R, Gralla J, Traber MG, Sokol RJ. Subcutaneous vitamin E ameliorates liver injury in an in vivo model of steatocholestasis. Hepatology. 2007; 46(2):485–95.
48. Sokol RJ, McKim JM Jr, Goff MC, Ruyle SZ, Devereaux MW, Han D, Packer L, Everson G. Vitamin E reduces oxidant injury to mitochondria and the hepatotoxicity of taurochenodeoxycholic acid in the rat. Gastroenterology. 1998; 114(1):164–74.
49. Azzi A, Gysin R, Kempna P, Munteanu A, Negis Y, Villacorta L, Visarius T, Zingg JM. Vitamin E mediates cell signaling and regulation of gene expression. Ann N Y Acad Sci. 2004; 1031:86–95.
50. Morante M, Sandoval J, Gomez-Cabrera MC, Rodriguez JL, Pallardo FV, Vina JR, Torres L, Barber T. Vitamin E deficiency induces liver nuclear factor-kappaB DNA-binding activity and changes in related genes. Free Radic Res. 2005; 39(10):1127–38.
51. Strieter RM, Remick DG, Ward PA, Spengler RN, Lynch JP 3rd, Larrick J, Kunkel SL. Cellular and molecular regulation of tumor necrosis factor-alpha production by pentoxifylline. Biochem Biophys Res Commun. 1988; 155(3):1230–6.
52. Bhat VB, Madyastha KM. Antioxidant and radical scavenging properties of 8-oxo derivatives of xanthine drugs pentoxifylline and lisofylline. Biochem Biophys Res Commun. 2001; 288(5):1212 7.
53. Koppe SW, Sahai A, Malladi P, Whitington PF, Green RM. Pentoxifylline attenuates steatohepatitis induced by the methionine choline deficient diet. J Hepatol. 2004; 41(4):592–8.
54. Puri P, Baillie RA, Wiest MM, Mirshahi F, Choudhury J, Cheung O, Sargeant C, Contos MJ, Sanyal AJ. A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology. 2007; 46(4):1081–90.
55. Lawitz EJ, Coste A, Poordad F, Alkhouri N, Loo N, McColgan BJ, Tarrant JM, Nguyen T, Han L, Chung C, Ray AS, et al. Acetyl-CoA Carboxylase Inhibitor GS-0976 for 12 Weeks Reduces Hepatic De Novo Lipogenesis and Steatosis in Patients with Nonalcoholic Steatohepatitis. Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association. 2018; 16(12):1983–1991.
56. Stiede K, Miao W, Blanchette HS, Beysen C, Harriman G, Harwood HJJR, Kelley H, Kapeller R, Schmalbach T, Westlin WF. Acetyl-coenzyme A carboxylase inhibition reduces de novo lipogenesis in overweight male subjects: A randomized, double-blind, crossover study. Hepatology. 2017; 66(2):324–334.
57. Hodson L, Fielding BA. Stearoyl-CoA desaturase: rogue or innocent bystander? Prog Lipid Res. 2013; 52(1):15–42.
58. Safadi R, Konikoff FM, Mahamid M, Zelber-Sagi S, Halpern M, Gilat T, Oren R, F. Group. The fatty acid-bile acid conjugate Aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2014; 12(12):2085–91
59. Ekstedt M, Franzen LE, Mathiesen UL, Holmqvist M, Bodemar G, Kechagias S. Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes: a histopathological follow-up study. J Hepatol. 2007; 47(1):135–41.
60. Taylor F, Huffman MD, Macedo AF, Moore TH, Burke M, Davey Smith G, *et al*. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2013.
61. Lonardo A, Ballestri S, Targher G, Loria P. Diagnosis and management of cardiovascular risk in nonalcoholic fatty liver disease. Expert Rev Gastroenterol Hepatol. 2015; 9(5):629–50.
62. Lewis JH, Mortensen ME, Zweig S, Fusco MJ, Medoff JR, Belder R, I. Pravastatin in Chronic Liver Disease Study. Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: Results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial. Hepatology. 2007; 46(5):1453–63.
63. Athyros VG, Tziomalos K, Gossios TD, Griva T, Anagnostis P, Kargiotis K, et al. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet. 2010; 376(9756):1916–22.
64. Min HK, Kapoor A, Fuchs M, Mirshahi F, Zhou H, Maher J, et al. Increased hepatic synthesis and dysregulation of cholesterol metabolism is associated with the severity of nonalcoholic fatty liver disease. Cell Metab. 2012; 15(5):665–74.
65. Jhaveri MA, Kowdley KV. New developments in the treatment of primary biliary cholangitis -Role of obeticholic acid. Ther Clin Risk Manag. 2017; 13:1053–1060.

66. Cariou B. The farnesoid X receptor (FXR) as a new target in non-alcoholic steatohepatitis. Diabetes Metab. 2008; 34(6 Pt 2):685–691.
67. Lefebvre P, Cariou B, Lien F, Kuipers F, Staels B. Role of bile acids and bile acid receptors in metabolic regulation. Physiol Rev. 2009; 89(1):147–191.
68. Kong B, Luyendyk JP, Tawfik O, Guo GL.Farnesoid X receptor deficiency induces nonalcoholic steatohepatitis in low-density lipoprotein receptor-knockout mice fed a high-fat diet. J Pharmacol Exp Ther. 2009; 328(1):116–22.
69. Fiorucci S, Rizzo G, Antonelli E, Renga B, Mencarelli A, Riccardi L,et al. A farnesoid x receptor-small heterodimer partner regulatory cascade modulates tissue metalloproteinase inhibitor-1 and matrix metalloprotease expression in hepatic stellate cells and promotes resolution of liver fibrosis. J Pharmacol Exp Ther. 2005; 314(2):584-95.
70. Ding L, Pang S, Sun Y, Tian Y, Yu L, Dang N. Coordinated Actions of FXR and LXR in Metabolism: From Pathogenesis to Pharmacological Targets for Type 2 Diabetes. Int J Endocrinol. 2014
71. Roda A, Pellicciari R, Gioiello A, Neri F, Camborata C, Passeri D, et al. Semisynthetic bile acid FXR and TGR5 agonists: physicochemical properties, pharmacokinetics, and metabolism in the rat. J Pharmacol Exp Ther. 2014; 350(1):56–68.
72. Tully DC, Rucker PV, Chianelli D, Williams J, Vidal A, Alper PB, et al. Discovery of Tropifexor (LJN452), a Highly Potent Non-bile Acid FXR Agonist for the Treatment of Cholestatic Liver Diseases and Nonalcoholic Steatohepatitis (NASH). J Med Chem. 2017; 60(24):9960–9973.
73. Pedrosa M, Seyedkazemi S, Francque S, Sanyal A, Rinella M, Charlton M, et al. A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial. Contemp Clin Trials. 2020; 88
74. Lamichane S, Dahal Lamichane B, Kwon SM. Pivotal Roles of Peroxisome Proliferator-Activated Receptors (PPARs) and Their Signal Cascade for Cellular and Whole-Body Energy Homeostasis. Int J Mol Sci. 2018; 19(4)
75. Kim H, Mendez R, Zheng Z, Chang L, Cai J, Zhang R, Zhang K. Liver-enriched transcription factor CREBH interacts with peroxisome proliferator-activated receptor alpha to regulate metabolic hormone FGF21. Endocrinology. 2014; 155(3):769–82.
76. Velkov T. Interactions between Human Liver Fatty Acid Binding Protein and Peroxisome Proliferator Activated Receptor Selective Drugs. PPAR Res. 2013
77. Qu S, Su D, Altomonte J, Kamagate A, He J, Perdomo G, et al. PPAR {alpha} mediates the hypolipidemic action of fibrates by antagonizing FoxO1. Am J Physiol Endocrinol Metab. 2007; 292(2): E421–34.
78. Mansouri RM, Bauge E, Staels B, Gervois P. Systemic and distal repercussions of liver-specific peroxisome proliferator-activated receptor-alpha control of the acute-phase response. Endocrinology. 2008; 149(6):3215–23.
79. Delerive P, De Bosscher K, Besnard S, Vanden Berghe W, Peters JM, Gonzalez FJ, et al. Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1. J Biol Chem. 1999; 274(45):32048–54.
80. Nagasawa T, Inada Y, Nakano S, Tamura T, Takahashi T, Maruyama K. Effects of bezafibrate, PPAR pan-agonist, and GW501516, PPARdelta agonist, on development of steatohepatitis in mice fed a methionine- and choline-deficient diet. Eur J Pharmacol. 2006; 536(1–2):182–91.
81. Ratziu V, Harrison SA, Francque S, Bedossa P, Lehert P, Serfaty L, et al. Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-alpha and -delta, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening. Gastroenterology. 2016; 150(5):1147–1159.
82. Tracey KJ, Cerami A. Tumor necrosis factor, other cytokines and disease. Annu Rev Cell Biol. 1993; 9:317–43.
83. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor alpha: direct role in obesity-linked insulin resistance. Science. 1993; 259(5091):87–91.
84. Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS. Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature. 1997; 389(6651):610–4
85. Moschen AR, Molnar C, Geiger S, Graziadei I, Ebenbichler CF, Weiss H, et al. Anti-inflammatory effects of excessive weight loss: potent suppression of adipose interleukin 6 and tumour necrosis factor alpha expression. Gut. 2010; 59(9):1259–64
86. Dandona P, Weinstock R, Thusu K, Abdel-Rahman E, Aljada A, Wadden T. Tumor necrosis factor-alpha in sera of obese patients: fall with weight loss. J Clin Endocrinol Metab. 1998; 83(8):2907–10.

87. Kern PA, Saghizadeh M, Ong JM, Bosch RJ, Deem R, Simsolo RB. The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. J Clin Invest. 1995; 95(5):2111–9.
88. Douglas HE. TGF-ss in wound healing: a review. J Wound Care. 2010;19(9):403–6.
89. Friedman SL. Cytokines and fibrogenesis. Semin Liver Dis. 1999; 19(2):129–40.
90. Shek FW, Benyon RC. How can transforming growth factor beta be targeted usefully to combat liver fibrosis? Eur J Gastroenterol Hepatol. 2004; 16(2):123–6.
91. Hellerbrand C, Stefanovic B, Giordano F, Burchardt ER, Brenner DA. The role of TGFbeta1 in initiating hepatic stellate cell activation in vivo. J Hepatol. 1999; 30(1):77–87.
92. Annoni G, Weiner FR, Zern MA. Increased transforming growth factor-beta 1 gene expression in human liver disease. J Hepatol. 1992; 14(2–3):259–64.
93. Fabregat I, Moreno-Càceres J, Sánchez A, Dooley S, Dewidar B, Giannelli G, ten Dijke P. TGF-β signalling and liver disease. FEBS J. 2016; 283:2219–2232.